PharmaCielo Announces Q3 2023 Financial Results
- None.
- The company reported a significant revenue decline from $475,000 in the third quarter of 2022 to $352,000 in the same period of 2023, indicating a decrease of approximately 25%. The adjusted EBITDA loss also decreased from $2,432,000 in 2022 to $1,370,000 in 2023, showing a positive trend but still indicating a loss. The net loss also decreased from $5,177,000 in 2022 to $2,761,000 in 2023, reflecting a positive trend but still a substantial loss. These financial figures indicate a challenging business environment for PharmaCielo.
All figures in Canadian dollars ($) unless otherwise specified
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - November 29, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the third quarter ended September 30, 2023.
Summary Financials
| Three months ended | ||||||||||
| (000's) | September 30 2023 | September 30 2022 | ||||||||
| Revenue | $ | 352 | $ | 475 | ||||||
| Adjusted EBITDA (Loss) | $ | (1,370 | ) | $ | (2,432 | ) | ||||
| Net Loss | $ | (2,761 | ) | $ | (5,177 | ) | ||||
| Net Loss per Share | $ | (0.02 | ) | $ | (0.03 | ) | ||||
For further detailed information and analysis, please see the financial statements and management's discussion and analysis for the period ending September 30, 2023, as posted at sedarplus.ca and pharmacielo.com.
Marc Lustig, Chairman and CEO, commented, "As the global cannabis market continues to develop and evolve, PharmaCielo is uniquely positioned to supply large, sophisticated, consumer and pharmaceutical product manufacturers. To our knowledge, there is no other company in the industry today who can consistently supply pharma-grade extracts and dried flower at the scale and with the cost advantage to that of PharmaCielo. As the cannabis market continues to develop and recover, we are in business development conversations and product testing with the most important players globally with a particular focus on the EU, Latin America, and Australia. Our team has built a focused and lean organization over the past twelve months, and effectively re-positioned the product portfolio on higher margin products. With total SG&A expenses down over
Summary of Recent Developments
- On October 6, 2023, PharmaCielo announced that it had raised
$1.5 million under its previously announced non-brokered private placement of debenture offering.
About PharmaCielo
PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable cultivating, processing and supply of all natural, pharmaceutical-grade medical dried cannabis flower and cannabis products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing center located in Rionegro, Colombia.
The board of directors and executive team of PharmaCielo are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location plays in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.
For further information
Ian Atacan, Chief Financial Officer
+1 416-562-3220
i.atacan@pharmacielo.com
Media and Investor Inquires:
investors@pharmacielo.com
*The term Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, & Amortization) does not have any standardized meaning under IFRS. Therefore, it may not be comparable to similar measures presented by other companies. The following table provides a reconciliation of net loss to adjusted EBITDA:
| Adjusted EBITDA | For the three months ended September 30, | | ||||||
| In CAD | 2023 | 2022 | | |||||
| Net loss for the period | $ | (2,761 | ) | $ | (5,177 | ) | | |
| Add back: | | |||||||
| Financing costs | 614 | 359 | | |||||
| Amortization of property, plant and equipment & intangible assets | 81 | 377 | | |||||
| Amortization expense included in production costs | 277 | 343 | | |||||
| EBITDA | $ | (1,789 | ) | $ | (4,098 | ) | | |
| Adjustments: | | |||||||
| Share based payments | 481 | 673 | | |||||
| Non-recurring expenses | (62 | ) | 993 | | ||||
| | | |||||||
| Adjusted EBITDA | $ | (1,370 | ) | $ | (2,432 | ) | | |
Forward-Looking Statements
This news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects", "is expected", "intends", "anticipates", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be completed or achieved. Forward-looking statements in this news release include, without limitation, statements regarding the issuance of the debenture units, including the timing and completion of any future issuances thereof.
The forward-looking statements in this news release are necessarily based on assumptions, including assumptions with respect to PharmaCielo's ability to obtain necessary approvals for the issuance of the debenture units.
Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including changes to PharmaCielo's development plans, the failure to obtain and maintain all necessary regulatory approvals relating to the export of cannabinoid products and the import of these products into other countries, TSX Venture Exchange approval, the inability to export or distribute commercial products through sales channels as anticipated due to economic or operational circumstances, risks associated with operating in Colombia, fluctuation of the market price for the Company's products, risks associated with global economic instability relating to COVID-19 or other developments, risks related to retention of key Company personnel, currency exchange risk, competition in PharmaCielo's market and other risks discussed or referred to under the heading "Risk Factors" in PharmaCielo's Annual Information Form for the financial year ended December 31, 2019, which is available at www.sedar.com. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/189041
FAQ
What are PharmaCielo Ltd.'s (TSXV: PCLO) financial results for the third quarter ended September 30, 2023?
Who is the Chairman and CEO of PharmaCielo Ltd. (TSXV: PCLO)?
What recent financial offering did PharmaCielo Ltd. (TSXV: PCLO) announce?
